Mental Health Startup Focused on Treatment-Resistant Patients Raises $2M in Seed Funding

Osmind — a mental health technology startup focused on treatment-resistant patients — has raised $2 million in seed funding, the company announced Wednesday.

The fundraising round was led by General Catalyst, with participation from What If Ventures, 20|20 Fund and various prominent health care executives, according to a press release announcing the news. Y Combinator and Pear VC also back Osmind.

Headquartered in Mountain View, California, Osmind is a public benefit corporation that builds software for mental health providers, while also generating clinical insights to advance the development of new therapies, diagnostics and care management programs.


Launched in June, Osmind aims to help providers and researchers tackle treatment-resistant mental health disorders, which are categorized as those that have been unsuccessfully treated twice or more with conventional methods such as medication and psychotherapy. 

This problem is especially prevalent, with about a third of people with depression considered to be treatment-resistant. 

“There are no objective measurements for what therapies work best for different people, leaving clinicians in the dark, researchers struggling to develop new treatments and patients suffering through a painful trial and error process,” Lucia Huang — co-founder and CEO of Osmind — said in a press release announcing the news. “Our software fits into a clinician’s existing workflow and patients enjoy using it. The platform then pulls in patient-reported outcomes, functional metrics and more. It analyzes how different patients respond to treatments, enabling clinicians to tailor their care and allowing researchers to develop better therapies and diagnostics.”


Osmind currently serves more than 125 practices across 30-plus states. It will use the new funding to accelerate the development and expansion of its electronic health record software and analytics platform.

Companies featured in this article: